R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL
Status:
Not yet recruiting
Trial end date:
2025-08-30
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated Phase 2 study, which combines R-EDOCH with Ibrutinib to
treat patients with Ritcher Transformation in consideration of DLBCL and CLL components both
could being targeted at the same time. The investigator will observe the 2-year overall
survival rate of this regimen for RT and explore the new regimen for RT in the novel drugs
era, which aims to improve the efficacy and prolong survival.